Impact of Non-Enzymatic Glycation in Neurodegenerative Diseases: Role of Natural Products in Prevention

Chapter
Part of the Advances in Neurobiology book series (NEUROBIOL, volume 12)

Abstract

Non-enzymatic protein glycosylation is the addition of free carbonyls to the free amino groups of proteins, amino acids, lipoproteins and nucleic acids resulting in the formation of early glycation products. The early glycation products are also known as Maillard reaction which undergoes dehydration, cyclization and rearrangement to form advanced glycation end-products (AGEs). By and large the researchers in the past have also established that glycation and the AGEs are responsible for most type of metabolic disorders, including diabetes mellitus, cancer, neurological disorders and aging. The amassing of AGEs in the tissues of neurodegenerative diseases shows its involvement in diseases. Therefore, it is likely that inhibition of glycation reaction may extend the lifespan of an individual. The hunt for inhibitors of glycation, mainly using in vitro models, has identified natural compounds able to prevent glycation, especially polyphenols and other natural antioxidants. Extrapolation of results of in vitro studies on the in vivo situation is not straightforward due to differences in the conditions and mechanism of glycation, and bioavailability problems. Nevertheless, existing data allow postulating that enrichment of diet in natural anti-glycating agents may attenuate glycation and, in consequence may halt the aging and neurological problems.

Keywords

Glycation Advanced glycation end-products (AGEs) Diabetes mellitus Neurological disorders Polyphenols 

Notes

Compliance with Ethics Requirements

The authors declare that they have no conflicts of interest.

References

  1. Ahmad S, Akhter F, Moinuddin, Shahab U, Khan MS. Studies on glycation of human low density lipoprotein: a functional insight into physico-chemical analysis. Int J Biol Macromol. 2013;62:167–71.CrossRefPubMedGoogle Scholar
  2. Ahmad S, Khan MS, Akhter F, et al. Glycoxidation of biological macromolecules: a critical approach to halt the menace of glycation. Glycobiology. 2014;24:979–90.CrossRefPubMedGoogle Scholar
  3. Akhter F, Hashim A, Khan MS, et al. Antioxidant, α-amylase inhibitory and oxidative DNA damage protective property of Boerhaavia diffusa (Linn.) root. South Afr J Bot. 2013;88:265–72.CrossRefGoogle Scholar
  4. Akhter F, Khan MS, Ahmad S. Acquired immunogenicity of calf thymus DNA and LDL modified by d-ribose: a comparative study. Int J Biol Macromol. 2014;72:1222–7.CrossRefPubMedGoogle Scholar
  5. Alam J, Cook JL. Transcriptional regulation of the heme oxygenase-1 gene via the stress response element pathway. Curr Pharm Des. 2003;9:2499–511.CrossRefPubMedGoogle Scholar
  6. Arasteh A, Farahi S, Habibi-Rezaei M, Moosavi-Movahedi AA. Glycated albumin: an overview of the in vitro models of an in vivo potential disease marker. J Diabetes Metab Disord. 2014;13:49.CrossRefPubMedPubMedCentralGoogle Scholar
  7. Ahmad S, Moinuddin, Dixit K, et al. Genotoxicity and immunogenicity of DNA-advanced glycation end products formed by methylglyoxal and lysine in presence of Cu2+. Biochem Biophys Res Commun. 2011; 407 (3): 568–574.Google Scholar
  8. Ahmad S, Shahab U, Baig MH, et al. Inhibitory effect of Metformin and Pyridoxamine in the formation of early, intermediate and advanced glycation end-products. PLoS ONE. 2013; 8 (9)e72128.Google Scholar
  9. Ashraf JM, Ahmad S, Rabbani G, et al. Physicochemical analysis of structural alteration and AGEs generation during glycation of H2A histone by 3-Deoxyglucosone. IUBMB Life, 2014; 66(10):686–93.Google Scholar
  10. Auluck PK, Caraveo G, Lindquist S. alpha-Synuclein: membrane interactions and toxicity in Parkinson’s disease. Annu Rev Cell Dev Biol. 2010;26:211–33.CrossRefPubMedGoogle Scholar
  11. Babu PV, Sabitha KE, Shyamaladevi CS. Effect of green tea extract on advanced glycation and cross-linking of tail tendon collagen in streptozotocin induced diabetic rats. Food Chem Toxicol. 2008;46:280–5.CrossRefPubMedGoogle Scholar
  12. Basta G, Lazzerini G, Del Turco S, et al. At least 2 distinct pathways generating reactive oxygen species mediate vascular cell adhesion molecule-1 induction by advanced glycation end products. Arterioscler Thromb Vasc Biol. 2005;25:1401–7.CrossRefPubMedGoogle Scholar
  13. Basta G, Castagnini M, Del Turco S, et al. High plasma levels of the soluble receptor for advanced glycation endproducts in patients with symptomatic carotid atherosclerosis. Eur J Clin Invest. 2009;39:1065–72.CrossRefPubMedGoogle Scholar
  14. Bennett MC. The role of alpha-synuclein in neurodegenerative diseases. Pharmacol Ther. 2005;105:311–31.CrossRefPubMedGoogle Scholar
  15. Berchtold NC, Cotman CW. Evolution in the conceptualization of dementia and Alzheimer’s disease: Greco-Roman period to the 1960s. Neurobiol Aging. 1998;19:173–89.CrossRefPubMedGoogle Scholar
  16. Beswick HT, Harding JJ. Conformational changes induced in lens alpha- and gamma-crystallins by modification with glucose 6-phosphate. Implications for cataract. Biochem J. 1987;246:761–9.CrossRefPubMedPubMedCentralGoogle Scholar
  17. Bierhaus A, Illmer T, Kasper M, et al. Advanced glycation end product (AGE)-mediated induction of tissue factor in cultured endothelial cells is dependent on RAGE. Circulation. 1997;96:2262–71.CrossRefPubMedGoogle Scholar
  18. Bourdon E, Loreau N, Blache D. Glucose and free radicals impair the antioxidant properties of serum albumin. FASEB J. 1999;13:233–44.PubMedGoogle Scholar
  19. Brown DR. Oligomeric alpha-synuclein and its role in neuronal death. IUBMB Life. 2010;62:334–9.PubMedGoogle Scholar
  20. Brownlee M. The pathological implications of protein glycation. Clin Invest Med. 1995;18:275.PubMedGoogle Scholar
  21. Burns A, Iliffe S. Alzheimer’s disease. BMJ (Clin Res Ed). 2009;338:b158.CrossRefGoogle Scholar
  22. Castellani R, Smith MA, Richey PJ, Petty G. Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease. Brain Res. 1996;737:195–200.CrossRefPubMedGoogle Scholar
  23. Chen X, de Silva HA, Pettenati MJ, et al. The human NACP/alpha-synuclein gene: chromosome assignment to 4q21.3–q22 and TaqI RFLP analysis. Genomics. 1995;26:425–7.CrossRefPubMedGoogle Scholar
  24. Chen M, Curtis TM, Stitt AW. Advanced glycation end products and diabetic retinopathy. Curr Med Chem. 2013;20:3234–40.CrossRefPubMedGoogle Scholar
  25. Chou SM, Wang HS, Taniguchi A, Bucala R. Advanced glycation end products in neurofilament conglomeration of motoneurons in familial and sporadic amyotrophic lateral sclerosis. Mol Med. 1998;4:324–32.PubMedPubMedCentralGoogle Scholar
  26. Choudhary MI, Maher S, Begum A. Characterization and antiglycation activity of phenolic constituents from Viscum album (European Mistletoe). Chem Pharm Bull. 2010;58:980–2.CrossRefPubMedGoogle Scholar
  27. Choudhuri S, Dutta D, Sen A, et al. Role of N-ε-carboxy methyl lysine, advanced glycation end products and reactive oxygen species for the development of nonproliferative and proliferative retinopathy in type 2 diabetes mellitus. Mol Vis. 2013;19:100–13.PubMedPubMedCentralGoogle Scholar
  28. Clifford MN. Chlorogenic acids and other cinnamates—nature, occurrence and dietary burden. J Sci Food Agric. 1999;79:362–72.CrossRefGoogle Scholar
  29. Curtis TM, Hamilton R, Yong PH, et al. Müller glial dysfunction during diabetic retinopathy in rats is linked to accumulation of advanced glycation end-products and advanced lipoxidation end-products. Diabetologia. 2011;54:690–8.CrossRefPubMedGoogle Scholar
  30. Dalfo E, Portero-Otin M, Ayala V, Martinez A, Pamplona R, Ferrer I. Evidence of oxidative stress in the neocortex in incidental Lewy body disease. J Neuropathol Exp Neurol. 2005;64:816–30.CrossRefPubMedGoogle Scholar
  31. DeGroot J, Verzijl N, Wenting-Van Wijk MJ, et al. Age-related decrease in susceptibility of human articular cartilage to matrix metalloproteinase-mediated degradation: the role of advanced glycation end products. Arthritis Rheum. 2001;44:2562–71.CrossRefPubMedGoogle Scholar
  32. Dexter DT, Carter CJ, Wells FR, et al. Basal lipid peroxidation in substantia nigra is increased in Parkinson’s disease. J Neurochem. 1989;52:381–9.CrossRefPubMedGoogle Scholar
  33. Drickamer K, Taylor ME. Introduction to glycobiology. 2nd ed. USA: Oxford University Press; 2006.Google Scholar
  34. Dugé de Bernonville T, Guyot S, Paulin JP. Dihydrochalcones: Implication in resistance to oxidative stress and bioactivities against advanced glycation end-products and vasoconstriction. Phytochemistry. 2010;71:443–52.CrossRefPubMedGoogle Scholar
  35. Dunn JA, McCance DR, Thorpe SR, Lyons TJ, Baynes JW. Age-dependent accumulation of N epsilon-(carboxymethyl)lysine and N epsilon-(carboxymethyl) hydroxylysine in human skin collagen. Biochemistry. 1991;30:1205–10.CrossRefPubMedGoogle Scholar
  36. Dworkin JP, Miller SL. A kinetic estimate of the free aldehyde content of aldoses. Carbohydr Res. 2000;329:359–65.CrossRefPubMedGoogle Scholar
  37. Dyer DG, Dunn JA, Thorpe SR. Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J Clin Invest. 1993;91:2463–9.CrossRefPubMedPubMedCentralGoogle Scholar
  38. El-Mesallamy HO, Hamdy NM, Ezzat OA, Reda AM. Levels of soluble advanced glycation end product-receptors and other soluble serum markers as indicators of diabetic neuropathy in the foot. J Investig Med. 2011;59:1233–8.CrossRefPubMedGoogle Scholar
  39. Fiuza SM, Gomes C, Teixeira LJ. Phenolic acid derivatives with potential anticancer properties—a structure-activity relationship study. Part 1: methyl, propyl and octyl esters of caffeic and gallic acids. Bioorg Med Chem. 2004;12:3581–9.CrossRefPubMedGoogle Scholar
  40. Frank RN. Diabetic retinopathy. N Engl J Med. 2004;350:48–58.CrossRefPubMedGoogle Scholar
  41. Giehm L, Svergun DI, Otzen DE, Vestergaard B. Low-resolution structure of a vesicle disrupting α-synuclein oligomer that accumulates during fibrillation. Proc Natl Acad Sci U S A. 2011;108:3246–51.CrossRefPubMedPubMedCentralGoogle Scholar
  42. Glenn JV, Beattie JR, Barrett L, et al. Confocal Raman microscopy can quantify advanced glycation end product (AGE) modifications in Bruch’s membrane leading to accurate, nondestructive prediction of ocular aging. FASEB J. 2007;21:3542–52.CrossRefPubMedGoogle Scholar
  43. Goedert M, Klug A, Crowther RA. Tau protein, the paired helical filament and Alzheimer disease. J Alzheimers Dis. 2006;9:195–207.PubMedGoogle Scholar
  44. Guerrero E, Vasudevaraju P, Hegde ML, Britton GB, Rao KS. Recent advances in α-synuclein functions, advanced glycation, and toxicity: implications for Parkinson's disease. Mol Neurobiol. 2013;47:525–36.CrossRefPubMedGoogle Scholar
  45. Gugliucci A, Bastos DH, Schulze J, Souza MF. Caffeic and chlorogenic acids in Ilex paraguariensis extracts are the main inhibitors of AGE generation by methylglyoxal in model proteins. Fitoterapia. 2009;80:339–44.CrossRefPubMedGoogle Scholar
  46. Gul A, Rahman MA, Hasnain SN, Salim A, Simjee SU. Could oxidative stress associate with age products in cataractogenesis? Curr Eye Res. 2008;33:669–75.CrossRefPubMedGoogle Scholar
  47. Harding JJ, Egerton M, van Heyningen R, Harding RS. Diabetes, glaucoma, sex, and cataract: analysis of combined data from two case control studies. Br J Ophthalmol. 1993;77:2–6.CrossRefPubMedPubMedCentralGoogle Scholar
  48. Harrington CR, Wischik CM, McArthur FK, Taylor GA, Edwardson JA, Candy JM. Alzheimer’s-disease-like changes in tau protein processing: association with aluminium accumulation in brains of renal dialysis patients. Lancet. 1994;343:993–7.CrossRefPubMedGoogle Scholar
  49. Hashim Z, Zarina S. Advanced glycation end products in diabetic and non-diabetic human subjects suffering from cataract. Age (Dordr). 2011;33:377–84.CrossRefGoogle Scholar
  50. Hashim A, Khan MS, Ahmad S. Alleviation of hyperglycemia and hyperlipidemia by Phyllanthus virgatus forst extract and its partially purified fraction in streptozotocin induced diabetic rats. EXCLI J. 2014;13:809–24.PubMedPubMedCentralGoogle Scholar
  51. Haus JM, Carrithers JA, Trappe SW, Trappe TA. Collagen, cross-linking, and advanced glycation end products in aging human skeletal muscle. J Appl Physiol. 2007;103:2068–76.CrossRefPubMedGoogle Scholar
  52. Herenkranz JR, Lewis NG, Kahn CR, Roth J. Phlorizin: a review. Diabetes Metab Res Rev. 2005;21:31–8.CrossRefGoogle Scholar
  53. Hernández I, Alegre L, Van Breusegem F, Munné-Bosch S. How relevant are flavonoids as antioxidant in plants? Trends Plant Sci. 2009;14:125–32.CrossRefPubMedGoogle Scholar
  54. Hsieh HM, Wu WM, Hu ML. Soy isoflavones attenuate oxidative stress and improve parameters related to aging and Alzheimer’s disease in C57BL/6J mice treated with D-galactose. Food Chem Toxicol. 2009;47:625–32.CrossRefPubMedGoogle Scholar
  55. Hsu FL, Lin IM, Kuo DH, Chen WC, Su HC, Cheng JT. Antihyperglycemic effect of puerarin in streptozotocin-induced diabetes rats. J Nat Prod. 2003;66:788–92.CrossRefPubMedGoogle Scholar
  56. Ichihashi M, Yagi M, Nomoto K, Yonei Y. Glycation stress and photo-aging in skin. Anti-Aging Med. 2011;8:23–9.CrossRefGoogle Scholar
  57. Iqbal D, Khan MS, Khan A, et al. In vitro screening for \( \beta \)-Hydroxy-\( \beta \)-methylglutaryl-CoA reductase inhibitory and antioxidant activity of sequentially extracted fractions of Ficus palmata Forsk. Biomed Res Int. 2014;14:1–10.CrossRefGoogle Scholar
  58. Jagtar AG, Patil PB. Antihyperglycemic activity and inhibition of advanced glycation end product formation by Cuminum cyminum in streptozotocin induced diabetic rats. Food Chem Toxicol. 2010;48:2030–6.CrossRefGoogle Scholar
  59. Jang DS, Yoo NH, Kim NH, et al. 3,5-Di-ocaffeoyl-epi-quinic acid from the leaves and stems of Erigeron annuus inhibits protein glycation, aldose reductase, and cataractogenesis. Biol Pharm Bull. 2010;33:329–33.CrossRefPubMedGoogle Scholar
  60. Jeanmaire C, Danoux L, Pauly G. Glycation during human dermal intrinsic and actinic ageing: an in vivo and in vitro model study. Br J Dermatol. 2001;145:10–8.CrossRefPubMedGoogle Scholar
  61. Kang J, Liu Y, Xie MX, Li S, Jiang M, Wang YD. Interactions of human serum albumin with chlorogenic acid and ferulic acid. Biochim Biophys Acta. 2004;1674:205–14.CrossRefPubMedGoogle Scholar
  62. Kawanishi K, Ueda H, Moriyasu M. Aldose reductase inhibitors from the nature. Curr Med Chem. 2003;10:1353–74.CrossRefPubMedGoogle Scholar
  63. Kayed R, Head E, Thompson JL, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 2003;300:486–9.CrossRefPubMedGoogle Scholar
  64. Kikuchi S, Shinpo K, Ogata A, et al. Detection of N-(carboxymethyl) lysine (CML) and non-CML advanced glycation end products in the anterior horn of amyotrophic lateral sclerosis spinal cord. Amyotroph Lateral Scler Other Motor Neuron Disord. 2002;3:63–8.CrossRefPubMedGoogle Scholar
  65. Kikuzaki H, Hisamoto M, Hirose K, Akiyama K, Taniguchi H. Antioxidant properties of ferulic acid and its related compounds. J Agric Food Chem. 2002;50:2161–8.CrossRefPubMedGoogle Scholar
  66. Kim J, Lee YM, Lee GY, Jang DS, Bae KH, Kim JS. Constituents of the Root of Pueraria lobata inhibit formation of advanced glycation end products (AGEs). Arch Pharm Res. 2006;29:821–5.CrossRefPubMedGoogle Scholar
  67. Kim KM, Jung DH, Jang DS, et al. Puerarin suppresses AGEs-induced inflammation in mouse mesangial cells: a possible pathway through the induction of heme oxygenase-1 expression. Toxicol Appl Pharmacol. 2010;244:106–13.CrossRefPubMedGoogle Scholar
  68. Kuhla A, Ludwig SC, Kuhla B, Münch G, Vollmar B. Advanced glycation end products are mitogenic signals and trigger cell cycle reentry of neurons in Alzheimer’s disease brain. Neurobiology. 2015;36:753–61.Google Scholar
  69. Kumar MS, Reddy PY, Kumar PA, Surolia I, Reddy GB. Effect of dicarbonyl-induced browning on alpha-crystallin chaperone-like activity: physiological significance and caveats of in vitro aggregation assays. Biochem J. 2004;379:273–82.CrossRefPubMedPubMedCentralGoogle Scholar
  70. Landis-Piwowar KR, Huo C, Chen D, et al. A novel prodrug of the green tea polyphenol (−)-epigallocatechin-3-gallate as a potential anticancer agent. Cancer Res. 2007;67:4303–10.CrossRefPubMedGoogle Scholar
  71. Ledesma MD, Bonary P, Colaco C, Avila J. Analysis of microtubule-associated protein tau glycation in paired helical filaments. J Biol Chem. 1994;269:21614–9.PubMedGoogle Scholar
  72. Lee DY, Chang GD. Methylglyoxal in cells elicits a negative feedback loop entailing transglutaminase 2 and glyoxalase 1. Redox Biol. 2014;2:196–205.CrossRefPubMedPubMedCentralGoogle Scholar
  73. Lee GY, Jang DS, Lee YM, Kim JM, Kim JS. Naphthopyrone glucosides from the seeds of Cassia tora with inhibitory activity on advanced glycation end products (AGEs) formation. Arch Pharm Res. 2006;29:587–90.CrossRefPubMedGoogle Scholar
  74. Lee D, Park CW, Paik SR, Choi KY. The modification of alpha-synuclein by dicarbonyl compounds inhibits its fibril-forming process. Biochim Biophys Acta. 2009;1794:421–30.CrossRefPubMedGoogle Scholar
  75. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095–128.CrossRefPubMedGoogle Scholar
  76. Lu J, Wu DM, Zheng YL, Hu B, Zhang ZF. Purple sweet potato color alleviates D-galactose-induced brain aging in old mice by promoting survival of neurons via PI3K pathway and inhibiting cytochrome C-mediated apoptosis. Brain Pathol. 2010;20:598–612.CrossRefPubMedGoogle Scholar
  77. Lu’o’ng K, Nguyen LT. Thiamine and Parkinson’s disease. J Neurol Sci. 2012;316:1–8.CrossRefPubMedGoogle Scholar
  78. Luthra M, Balasubramanian D. Nonenzymatic glycation alters protein structure and stability. A study of two eye lens crystallins. J Biol Chem. 1993;268:18119–27.PubMedGoogle Scholar
  79. Ma HY, Gao HY, Sun L, Huang J, Xu XM, Wu LJ. Constituents with α-glucosidase and advanced glycation end-product formation inhibitory activities from Salvia miltiorrhiza Bge. J Nat Med. 2011;65:37–42.CrossRefPubMedGoogle Scholar
  80. Makita Z, Bucala R, Rayfield EJ, et al. Reactive glycosylation endproducts in diabetic uremia and treatment of renal failure. Lancet. 1994;343:1519–22.CrossRefPubMedGoogle Scholar
  81. Manzanaro S, Salva J, de la Fuente JA. Phenolic marine natural products as aldose reductase inhibitors. J Nat Prod. 2006;69:1485–7.CrossRefPubMedGoogle Scholar
  82. Mao GX, Deng HB, Yuan LG, Li DD, Li YY, Wang Z. Protective role of salidroside against aging in a mouse model induced by D-galactose. Biomed Environ Sci. 2010;23:161–6.CrossRefPubMedGoogle Scholar
  83. Matsuda H, Wang T, Managi H, Yoshikawa M. Structural requirements of flavonoids for inhibition of protein glycation and radical scavenging activities. Bioorg Med Chem. 2003;11:5317–23.CrossRefPubMedGoogle Scholar
  84. Mazur WM, Duke JA, Wahala K, Rasku S, Adlercreutz H. Isoflavonoids and lignans in legumes: nutritional and heath aspects in humans. J Nutr Biochem. 1998;9:193–200.CrossRefGoogle Scholar
  85. Melpomeni P, Uribarri J, Vlassara H. Glucose, advanced glycation end products, and diabetes complications: what is new and what works. Clin Diabetes. 2003;21:186–7.CrossRefGoogle Scholar
  86. Meng J, Sakata N, Takebayashi S, et al. Glycoxidation in aortic collagen from STZ-induced diabetic rats and its relevance to vascular damage. Atherosclerosis. 1998;136:355–65.CrossRefPubMedGoogle Scholar
  87. Meng G, Zhu H, Yang S, et al. Attenuating effects of Ganoderma lucidum polysaccharides on myocardial collagen cross-linking relates to advanced glycation end product and antioxidant enzymes in high-fat-diet and streptozotocin-induced diabetic rats. Carbohydr Polym. 2011;84:180–5.CrossRefGoogle Scholar
  88. Miroliaei M, Khazaei S, Moshkelgosha S, Shirvani M. Inhibitory effects of Lemon balm (Melissa officinalis, L.) extract on the formation of advanced glycation end products. Food Chem. 2011;129:267–71.CrossRefGoogle Scholar
  89. Mizutari K, Ono T, Ikeda K, Kayashima K, Horiuchi S. Photo-enhanced modification of human skin elastin in actinic elastosis by N(epsilon)-(carboxymethyl)lysine, one of the glycoxidation products of the Maillard reaction. J Invest Dermatol. 1997;108:797–802.CrossRefPubMedGoogle Scholar
  90. Monnier VM, Stevens VJ, Cerami A. Maillard reactions involving proteins and carbohydrates in vivo: relevance to diabetes mellitus and aging. Prog Food Nutr Sci. 1981;5:315–27.PubMedGoogle Scholar
  91. Munch G, Mayer S, Michaelis J. Influence of advanced glycation end-products and AGE-inhibitors on nucleation-dependent polymerization of β-amyloid peptide. Biochim Biophys Acta Mol Basis Dis. 1997;1360:17–29.CrossRefGoogle Scholar
  92. Munch G, Schinzel R, Loske C, et al. Alzheimer’s disease-synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts. J Neural Transm. 1998;105:439–61.CrossRefPubMedGoogle Scholar
  93. Munch G, Luth HJ, Wong A. Crosslinking of alpha-synuclein by advanced glycation endproduct—an early pathophysiological step in Lewy body formation ? J Chem Neuroanat. 2000;20:253–7.CrossRefPubMedGoogle Scholar
  94. Mustafa I, Ahmad S, Dixit K, Ahmad J, Ali A. Glycated human DNA is a preferred antigen for anti-DNA antibodies in diabetic patients. Diabetes Res Clin Pract. 2011;95:98–104.CrossRefPubMedGoogle Scholar
  95. Nagaraj RH, Linetsky M, Stitt AW. The pathogenic role of Maillard reaction in the aging eye. Amino Acids. 2012;42:1205–20.CrossRefPubMedGoogle Scholar
  96. Negre-Salvayre A, Salvayre R, Augé N, Pamplona R, Portero-Otín M. Hyperglycemia and glycation in diabetic complications. Antioxid Redox Signal. 2009;11:3071–109.CrossRefPubMedGoogle Scholar
  97. Nowotny K, Jung T, Grune T, Hohn A. Accumulation of modified proteins and aggregate formation in aging. Exp Gerontol. 2014;57:122–31.CrossRefPubMedGoogle Scholar
  98. Obeso JA, Goetz CG, Rodriguez-Oroz MC, et al. Missing pieces in the Parkinson’s disease puzzle. Nat Med. 2010;16:653–61.CrossRefPubMedGoogle Scholar
  99. Peng X, Zheng Z, Cheung KW, Shan F, Ren GX, Chen SF, Wang M. Inhibitory effect of mung bean extract and its constituents vitexin and isovitexin on the formation of advanced glycation endproducts. Food Chem. 2008;106:457–81.CrossRefGoogle Scholar
  100. Peppa M, Uribarri J, Vlassara H. Aging and glycoxidant stress. Hormones (Athens). 2008;7:123–32.Google Scholar
  101. Peters T. Science Direct: all about albumin: biochemistry, genetics, and medical applications. San Diego, CA: Academic Press; 1996.Google Scholar
  102. Pontias I, Treutter D, Paulin JP, Brisset MN. Erwinia amylovora modifies phenolic profiles of susceptible and resistant apple through its type III secretion system. Physiol Plant. 2008;132:262–71.CrossRefGoogle Scholar
  103. Querfurth HW, LaFerla FM. Alzheimer’s disease. N Engl J Med. 2010;362:329–44.CrossRefPubMedGoogle Scholar
  104. Rabbani N, Godfrey L, Xue M, et al. Glycation of LDL by methylglyoxal increases arterial atherogenicity. Diabetes. 2011;60(7):1973–80.CrossRefPubMedPubMedCentralGoogle Scholar
  105. Raheem M, Iram S, Khan MS, et al. Glycation-assisted synthesized gold nanoparticles inhibit growth of bone cancer cells, Colloid and Surfaces-B. 2014; 117:473–9.Google Scholar
  106. Ramasamy R, Vannucci SJ, Yan SS, Herold K, Yan SF, Schmidt AM. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology. 2005;15:16R–28.CrossRefPubMedGoogle Scholar
  107. Reddy VP, Beyaz A. Inhibitors of the Maillard reaction and AGE breakers as therapeutics for multiple diseases. Drug Discov Today. 2006;11(13-14):646–54.CrossRefPubMedGoogle Scholar
  108. Revett TJ, Baker GB, Jhamandas J, Kar S. Glutamate system, amyloid ß peptides and tau protein: functional interrelationships and relevance to Alzheimer disease pathology. J Psychiatry Neurosci. 2013;38:6–23.CrossRefPubMedPubMedCentralGoogle Scholar
  109. Rimbach G, Boesh-Saadatmandi C, Frank J, et al. Dietary isoflavones in the prevention of cardiovascular disease: a molecular perspective. Food Chem Toxicol. 2008;46:1308–19.CrossRefPubMedGoogle Scholar
  110. Riviere S, Birlouez-Aragon I, Vellas B. Plasma protein glycation in Alzheimer’s disease. Glycoconj J. 1998;15:1039–42.CrossRefPubMedGoogle Scholar
  111. Sasaki N, Fukatsu R, Tsuzuki K, et al. Advanced glycation end products in Alzheimer’s disease and other neurodegenerative diseases. Am J Pathol. 1998;153:1149–55.CrossRefPubMedPubMedCentralGoogle Scholar
  112. Sasaki N, Toki S, Choei H, Saito T, Nakano N, Hayashi Y, et al. Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer’s disease. Brain Res. 2001;888:256–62.CrossRefPubMedGoogle Scholar
  113. Sasaki N, Takeuchi M, Choei H, et al. Advanced glycation end products (AGE) and their receptor (RAGE) in the brain of patients with Creutzfeldt-Jakob disease with prion plaques. Neurosci Lett. 2002;326:117–20.CrossRefPubMedGoogle Scholar
  114. Schapira AH. Mitochondrial diseases. Lancet. 2012;379:1825–34.CrossRefPubMedGoogle Scholar
  115. Schapira AH. Recent developments in biomarkers in Parkinson disease. Curr Opin Neurol. 2013;26:395–400.CrossRefPubMedPubMedCentralGoogle Scholar
  116. Schipper HM. Brain iron deposition and the free radical-mitochondrial theory of ageing. Ageing Res Rev. 2004;3:265–301.CrossRefPubMedGoogle Scholar
  117. Schleicher ED, Wagner E, Nerlich AG. Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. J Clin Invest. 1997;99:457–68.CrossRefPubMedPubMedCentralGoogle Scholar
  118. Schmidt AM, Hori O, Chen JX, et al. Advanced glycation end products interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest. 1995;96:1395–403.CrossRefPubMedPubMedCentralGoogle Scholar
  119. Schrag A, Schott JM. Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism. Lancet Neurol. 2006;5:355–63.CrossRefPubMedGoogle Scholar
  120. Selkoe DG. Normal and abnormal biology of the b-amyloid precursor protein. Annu Rev Neurosci. 1994;17:489–517.CrossRefPubMedGoogle Scholar
  121. Sell DR, Carlson EC, Monnier VM. Differential effects of type 2 (non-insulin-dependent) diabetes mellitus on pentosidine formation in skin and glomerular basement membrane. Diabetologia. 1993;36:936–41.CrossRefPubMedGoogle Scholar
  122. Sell DR, Lane MA, Johnson WA. Longevity and the genetic determination of collagen glycoxidation kinetics in mammalian senescence. Proc Natl Acad Sci U S A. 1996;93:485–90.CrossRefPubMedPubMedCentralGoogle Scholar
  123. Severin FF, Feniouk BA, Skulachev VP. Advanced glycation of cellular proteins as a possible basic component of the “master biological clock”. Biochemistry (Mosc). 2013;78:1043–7.CrossRefGoogle Scholar
  124. Shahab U, Tabrez S, Khan MS, et al. Immunogenicity of DNA-advanced glycation end product fashioned through glyoxal and arginine in the presence of Fe3+: its potential role in prompt recognition of diabetes mellitus auto-antibodies. Chemico Biol Int. 2014; 219; 229–240.Google Scholar
  125. Shaffer JL, Petrella JR, Sheldon FC, et al. Alzheimer’s disease neuroimaging initiative. Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinal fluid, MR imaging, and PET biomarkers. Radiology. 2013;266:583–91.CrossRefPubMedPubMedCentralGoogle Scholar
  126. Shaikh S, Nicholson LF. Advanced glycation end products induce in vitro cross-linking of alpha-synuclein and accelerate the process of intracellular inclusion body formation. J Neurosci Res. 2008;86:2071–82.CrossRefPubMedGoogle Scholar
  127. Shin DC, Kim CT, Lee YC, Choi WJ, Na YJ. Reduction of acrylamide by taurine in aqueous and potato chip model systems. Food Res Int. 2010;43:1356–60.CrossRefGoogle Scholar
  128. Shuvaev V, Laffont I, Serot JM, Fujii J, Taniguchi N, Siest G. Increased protein glycation in cerebrospinal fluid of Alzheimer’s disease. Neurobiol Aging. 2001;22:397–402.CrossRefPubMedGoogle Scholar
  129. Smith MA, Taneda S, Richey PL, et al. Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc Natl Acad Sci U S A. 1994;91:5710–4.CrossRefPubMedPubMedCentralGoogle Scholar
  130. Stadler RH, Blank I, Varga N, et al. Acrylamide from Maillard reaction products. Nature. 2002;419:449–50.CrossRefPubMedGoogle Scholar
  131. Stitt AW. Advanced glycation: an important pathological event in diabetic and age related ocular disease. Br J Ophthalmol. 2001;85:746–53.CrossRefPubMedPubMedCentralGoogle Scholar
  132. Stitt AW, Hughes SJ, Canning P, et al. Substrates modified by advanced glycation end-products cause dysfunction and death in retinal pericytes by reducing survival signals mediated by platelet-derived growth factor. Diabetologia. 2004;47:1735–46.CrossRefPubMedGoogle Scholar
  133. Sugimoto K, Nishizawa Y, Horiuchi S, Yagihashi S. Localization in human diabetic peripheral nerve of N(epsilon)-carboxymethyllysine-protein adducts, an advanced glycation endproduct. Diabetologia. 1997;40:1380–7.CrossRefPubMedGoogle Scholar
  134. Sun Z, Peng X, Liu J, Fan K-W, Wang M, Chen F. Inhibitory effect of microalgal extracts on the formation of advanced glycation endproducts (AGEs). Food Chem. 2010;120:261–7.CrossRefGoogle Scholar
  135. Sun Z, Liu J, Zeng X, et al. Astaxanthin is responsible for antiglycoxidative properties of microalga Chlorella zofingiensis. Food Chem. 2011;126:1629–35.CrossRefPubMedGoogle Scholar
  136. Swardfager W, Lanctôt K, Rothenburg L, Wong A, Cappell J, Herrmann N. A meta-analysis of cytokines in Alzheimer disease. Biol Psychiatry. 2010;68:930–41.CrossRefPubMedGoogle Scholar
  137. Takeuchi M, Makita Z, Yanagisawa K, Kameda Y, Koike T. Detection of noncarboxymethyllysine and carboxymethyllysine advanced glycation end products (AGE) in serum of diabetic patients. Mol Med. 1999;5:393–405.PubMedPubMedCentralGoogle Scholar
  138. Takeuchi M, Iwaki M, Takino JI, et al. Immunological detection of fructose-derived advanced glycation end-products. Lab Invest. 2010;90:1117–27.CrossRefPubMedGoogle Scholar
  139. Terao J, Kawai Y, Murota K. Vegetable flavonoids and cardiovascular disease. Asia Pac J Clin Nutr. 2008;17:291–3.PubMedGoogle Scholar
  140. Thornalley PJ. Glutathione-dependent detoxification of alpha-oxoaldehydes by the glyoxalase system: involvement in disease mechanisms and antiproliferative activity of glyoxalase l inhibitor. Chem Biol Interact. 1998;112:137–51.CrossRefGoogle Scholar
  141. Thornalley PJ. Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. Arch Biochem Biophys. 2003;419:31–40.CrossRefPubMedGoogle Scholar
  142. Tsao R. Chemistry and biochemistry of dietary polyphenols. Nutrients. 2010;2:1231–46.CrossRefPubMedPubMedCentralGoogle Scholar
  143. Tsuji-Naito K, Saeki H, Hamano M. Inhibitory effects of Chrysanthemum species extracts on formation of advanced glycation end products. Food Chem. 2009;116:854–9.CrossRefGoogle Scholar
  144. Uribarri J, Cai W, Peppa M, et al. Circulating glycotoxins and dietary advanced glycation endproducts: two links to inflammatory response, oxidative stress, and aging. J Gerontol A Biol Sci Med Sci. 2007;62:427–33.CrossRefPubMedPubMedCentralGoogle Scholar
  145. Van Puyvelde K, Mets T, Njemini R, Beyer I, Bautmans I. Effect of advanced glycation end product intake on inflammation and aging: A systematic review. Nutr Rev. 2014;72:638–50.CrossRefPubMedGoogle Scholar
  146. Van Rooijen BD, Claessens MM, Subramaniam V. Membrane permeabilization by oligomeric alpha-synuclein: in search of the mechanism. PLoS One. 2010;5:e14292.CrossRefPubMedPubMedCentralGoogle Scholar
  147. Vasan S, Foiles P, Founds H. Therapeutic potential of breakers of advanced glycation end product-protein crosslinks. Arch Biochem Biophys. 2003;419:89–96.CrossRefPubMedGoogle Scholar
  148. Vasu VT, Modi H, Thaikoottathil JV, Gupta S. Hypolipidaemic and antioxidant effect of Enicostemma littorale Blume aqueous extract in cholesterol fed rats. J Ethnopharmacol. 2005;101:277–82.CrossRefPubMedGoogle Scholar
  149. Verzelloni E, Tagliazucchi D, Rio D, Calani L, Conte A. Antiglycative and antioxidative properties of coffee fractions. Food Chem. 2011;124:1430–5.CrossRefGoogle Scholar
  150. Verzijl N, DeGroot J, Oldehinkel E, et al. Age-related accumulation of Maillard reaction products in human articular cartilage collagen. Biochem J. 2000a;350:381–7.CrossRefPubMedPubMedCentralGoogle Scholar
  151. Verzijl N, DeGroot J, Thorpe SR, et al. Effect of collagen turnover on the accumulation of advanced glycation end products. J Biol Chem. 2000b;275:39027–31.CrossRefPubMedGoogle Scholar
  152. Vinson JA, Proch J, Bose P, et al. Chocolate is a powerful ex vivo and in vivo antioxidant, an antiatherosclerotic agent in an animal model, and a significant contributor to antioxidants in the European and American diets. J Agric Food Chem. 2006;54:8071–6.CrossRefPubMedGoogle Scholar
  153. Vitek MP, Bhattacharya K, Glendening JM, et al. Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc Natl Acad Sci U S A. 1994;91:4766–70.CrossRefPubMedPubMedCentralGoogle Scholar
  154. Vlassara H, Brownlee M, Cerami A. Nonenzymatic glycosylation of peripheral nerve protein in diabetes mellitus. Proc Natl Acad Sci U S A. 1981;78:5190–2.CrossRefPubMedPubMedCentralGoogle Scholar
  155. Vlassara H, Cai W, Crandall J, et al. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci U S A. 2002;99:15596–601.CrossRefPubMedPubMedCentralGoogle Scholar
  156. Volles MJ, Lansbury PT. Zeroing in on the pathogenic form of alphasynuclein and its mechanism of neurotoxicity in Parkinson's disease. Biochemistry. 2003;42:7871–8.CrossRefPubMedGoogle Scholar
  157. Wang PC, Zhang J, Zhang ZY, Tong TJ. Aminoguanidine delays the replicative senescence of human diploid fibroblasts. Chin Med J. 2007;120:2028–35.PubMedGoogle Scholar
  158. Wang J, Sun B, Cao Y, Tian Y. Protein glycation inhibitory activity of wheat bran feruloyl oligosaccharides. Food Chem. 2009;112:350–3.CrossRefGoogle Scholar
  159. Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, Wautier JL. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab. 2001;280:E685–94.PubMedGoogle Scholar
  160. Wei Y, Chen L, Chen J, Ge L, He RQ. Rapid glycation with D-ribose induces globular amyloid-like aggregations of BSA with high cytotoxicity to SH-SY5Y cells. BMC Cell Biol. 2009;10:10.CrossRefPubMedPubMedCentralGoogle Scholar
  161. Whitton PS. Inflammation as a causative factor in the aetiology of Parkinson’s disease. Br J Pharmacol. 2007;150:963–76.CrossRefPubMedPubMedCentralGoogle Scholar
  162. Williams AH. Dihydrochalcones; their occurrence and use as indicators in plant chemical taxonomy. Nature. 1964;202:824–5.CrossRefGoogle Scholar
  163. Yan SD, Chen X, Schmidt AM, et al. Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress. Proc Natl Acad Sci U S A. 1994;91:7787–91.CrossRefPubMedPubMedCentralGoogle Scholar
  164. Yan SD, Chen X, Fu J, et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer’s disease. Nature. 1996;382:685–91.CrossRefPubMedGoogle Scholar
  165. Yazdanparast R, Ardestani A, Jamshidi S. Experimental diabetes treated with Achillea santolina: effect on pancreatic oxidative parameters. J Ethnopharmacol. 2007;112:13–8.CrossRefPubMedGoogle Scholar
  166. Zeevalk GD, Razmpour R, Bernard LP. Glutathione and Parkinson’s disease: is this the elephant in the room? Biomed Pharmacother. 2008;62:236–49.CrossRefPubMedGoogle Scholar
  167. Zhou C, Huang Y, Przedborski S. Oxidative stress in Parkinson’s disease: a mechanism of pathogenic and therapeutic significance. Ann N Y Acad Sci. 2008;1147:93–104.CrossRefPubMedPubMedCentralGoogle Scholar
  168. Zong H, Ward M, Stitt AW. AGEs, RAGE, and diabetic retinopathy. Curr Diab Rep. 2011;11:244–52.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Laboratory of Glycation Biology and Metabolic Disorder, Integral Research Centre-I, Department of Bio-sciencesIntegral UniversityLucknowIndia

Personalised recommendations